WS
AEGR

Wedbush Securities’s Aegerion Pharmaceuticals AEGR Stock Holding History

Wedbush Securities’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-20,000
Closed -$30K – 885
2016
Q2 		$30K Buy
+20,000
New +$45.8K ﹤0.01% 754

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Wedbush Securities's AEGR Position: Q3 2016 in Review

Wedbush Securities sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2016, closing a stake of 20,000 shares — an estimated $30K sold.

Wedbush Securities first reported a position in AEGR in Q2 2016 and held it in 1 quarter. The position peaked at $30K in Q2 2016. 58 funds tracked by Wall St. Rank hold AEGR as of Q3 2016.

  • Wedbush Securities reported no remaining Aegerion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Wedbush Securities sold 20,000 Aegerion Pharmaceuticals shares in Q3 2016, an estimated $30K.
  • Wedbush Securities first reported a position in Aegerion Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Wedbush Securities's Aegerion Pharmaceuticals position peaked at $30K in Q2 2016.
  • 58 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2016.

Based on Wedbush Securities's 13F filing for Q3 2016, filed 4 Nov 2016.